Bone marrow proliferation

Bone marrow proliferation refers to the physiological process by which hematopoietic stem cells and their progenitor derivatives undergo division and maturation within the bone marrow cavity [1]. This process is essential for the continuous replacement of circulating blood cells, including erythrocytes, leukocytes, and platelets, and is tightly regulated by a complex network of cytokines, growth factors, and the marrow microenvironment [2]. Pathologically, autonomous or excessive bone marrow proliferation is the defining feature of myeloproliferative neoplasms (MPNs) and leukemias, often driven by driver mutations in signaling molecules like JAK2 or BCR-ABL1 [3]. Conversely, impaired bone marrow proliferation results in cytopenias or bone marrow failure syndromes, which can be idiopathic or secondary to cytotoxic chemotherapy [4]. Clinical interventions aim to either stimulate this process using recombinant growth factors like G-CSF or suppress it using targeted kinase inhibitors (e.g., Ruxolitinib) or cytoreductive agents to restore normal hematologic balance [5]. Because 'Bone marrow proliferation' is a physiological state or clinical observation rather than a specific molecular entity, it is typically considered a phenotypic endpoint rather than a primary therapeutic target [6].

Other names

Hematopoietic cell proliferationMyeloproliferationHematopoiesisBone marrow cellularityMyelopoiesis

Modulation of hematopoietic growth factor receptors (e.g., G-CSFR, EPOR) and downstream signaling pathways such as JAK/STAT, or direct inhibition of DNA synthesis in rapidly dividing myeloid cells.